Paternal exposure to irbesartan coadministered with multiple antihypertensive and antidiabetic drugs: A case report of a baby born healthy

Soon Cheol Hong, Jung Yeol Han, June Seek Choi, Hyun Kyong Ahn, E. Yadira Velázquez-Armenta, Alejandro A. Nava-Ocampo

Research output: Contribution to journalArticle

1 Citation (Scopus)


Objective: To report the fetal outcome of a baby with paternal exposure to irbesartan and other antihypertensive and antidiabetic drugs. Case: The baby was conceived by in vitro fertilization with an egg obtained from a woman with untreated diabetes and hypertension and the sperm from a male with type-2 diabetes and hypertension. At the time of sperm donation, he was taking irbesartan 150 mg d-1 in addition to amlodipine, aspirin, carvedilol, glibenclamide, hydrochlorothiazide, metformin, ramipril, and triazolam. At 38 weeks gestation, a 3,090 g female baby was delivered by cesarean section due to placenta previa. At 40 months postnatal age, the baby was 18 kg with normal growth and development. Conclusion: This case suggests that paternal exposure to irbesartan as part of a combination therapy with other antihypertensive drugs and antidiabetics, does not alter sperm cells or increase the risk for fetal malformations.

Original languageEnglish
Pages (from-to)24-26
Number of pages3
JournalJournal of Clinical Pharmacology and Pharmacoepidemiology
Issue number1
Publication statusPublished - 2010 Jun 15



  • Angiotensin II type 1 receptor blockers
  • Antihypertensive agents
  • Paternal exposure
  • Sartans

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Epidemiology
  • Pharmacology

Cite this